Accelerated approval is supported by 34-week interim data from the phase 3 I CAN trial showing a statistically significant 43% placebo-adjusted reduction in proteinuria.
The new 150mg oral pellet formulation provides a capsule-free prophylactic option for adults and adolescents with hereditary ...
Enzyme-inducing ASDs increase risk for incident osteoporosis or osteopenia, but few patients receive vitamin D supplementation.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
HealthDay News — Benzodiazepine use in pregnancy is not associated with an increased risk for major congenital malformations, according to a study published online October 13 in the Annals of Internal ...
A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms and preventing postmenopausal ...
The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer ...
A new liquid formulation of cevimeline HCl offers a bioequivalent alternative for adult patients experiencing dry mouth ...
Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...
The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer disease.
Dostarlimab-gxly demonstrated high rates of sustained clinical complete response that allowed eligible patients to avoid chemotherapy, radiation, and surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results